Literature DB >> 23161304

Risk factors for higher anti-HCV positivity in a border city in southern Turkey with unique population characteristics.

Birol Özer1, Gülşah Seydaoğlu, Akatlı Kürşat Özşahın, Hakan Demırhındı.   

Abstract

BACKGROUND/AIMS: This study was conducted as a seroprevalence study on hepatitis C virus infection in a small city located in southern Anatolia, to estimate the prevalence of hepatitis C virus and to explore the potential risk factors for hepatitis C virus infection at this population level.
MATERIAL AND METHODS: A total of 1427 (685 male (48%), 742 female) subjects agreed to participate in the study. Risk factors were examined using a questionnaire. All blood samples were tested using third-generation anti-hepatitis C virus enzyme-linked immunosorbent assays.
RESULTS: The overall anti-hepatitis C virus prevalence was 3.1% (44/1427). There was a steady rise in the prevalence of anti-hepatitis C virus positivity with age; the anti-hepatitis C virus prevalence was slightly higher in men (3.6%) than women (2.6%). The prevalence of anti-hepatitis C virus positivity was significantly higher in primary school graduates (3.4%) (odds ratio [OR]: 4.1, 95% confidence interval [CI]: 1.5-11.6, p=0.0001) and in illiterate subjects (5.0%) (OR: 2.7, 95% CI: 1.1-7.4, p=0.021) compared to secondary-plus graduates. Anti-hepatitis C virus positivity was higher (3.7%) in married subjects (OR: 8.7, 95% CI: 1.2-63.7, p=0.003) compared to single subjects (0.0%). Having dental procedure, delivery at home, provocative abortion, working abroad, hypertension, and diabetes mellitus were factors found to increase the anti-hepatitis C virus positivity significantly.
CONCLUSIONS: In the region of the current study, the anti-hepatitis C virus seroprevalence was higher compared to the whole country. Illiteracy, previous dental procedures, and working abroad in neighboring countries seem to be factors that relate to this high ratio.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23161304     DOI: 10.4318/tjg.2012.0554

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  7 in total

1.  Characterization of the Interleukin-28B Gene rs12979860 C/T Polymorphism in Turkish Chronic Hepatitis C Patients and Healthy Individuals.

Authors:  Serpil Taheri; Bilgehan Aygen; Keziban Korkmaz; Orhan Yıldız; Gökmen Zararsız; Halit Canatan
Journal:  Balkan Med J       Date:  2015-04-01       Impact factor: 2.021

2.  Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey.

Authors:  Necati Örmeci; Simten Malhan; İsmail Balık; Gül Ergör; Homie Razavi; Sarah Robbins
Journal:  Hepatol Int       Date:  2017-10-12       Impact factor: 6.047

3.  Prioritizing High-Risk Practices and Exploring New Emerging Ones Associated With Hepatitis C Virus Infection in Egypt.

Authors:  Ammal Metwally; Amira Mohsen; Rehan Saleh; Walaa Foaud; Nihad Ibrahim; Thanaa Rabaah; Manal El-Sayed
Journal:  Iran J Public Health       Date:  2014-10       Impact factor: 1.429

4.  Impact of Interleukin 28B Genotype on the Virological Responses in Chronic Hepatitis C Treatment.

Authors:  Bilgehan Aygen; Orhan Yildiz; Sila Akhan; Ozgur Gunal; Serpil Taheri; Gokmen Zararsiz; Murat Sayan; Aydin Rustemoglu; Elif Sargin Altinok
Journal:  Gastroenterology Res       Date:  2014-12-27

5.  Prevalence of hepatitis B, C, and HIV among patients attending a teaching dental hospital. A 7-year retrospective study from the United Arab Emirates.

Authors:  Suhail H Al-Amad
Journal:  Saudi Med J       Date:  2018-05       Impact factor: 1.484

6.  Willingness of dentists in the United Arab Emirates to perform restorative and surgical treatments for patients infected with hepatitis C.

Authors:  Suhail H Al-Amad
Journal:  Arch Public Health       Date:  2021-12-22

7.  Serological test results of sexually transmitted diseases in patients with condyloma acuminata.

Authors:  Emine Ünal; Müzeyyen Gönül; Seray Çakmak; Ayşegül Yalçınkaya Iyidal; Arzu Kılıç; Ülker Gül; Pinar Doner
Journal:  Postepy Dermatol Alergol       Date:  2015-08-12       Impact factor: 1.837

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.